PSA密度在Göteborg-2试验MRI阴性男性随访中的作用
该研究基于Göteborg-2随机筛查试验,纳入1685例初次MRI阴性(PI-RADS≤2)的男性,评估PSAD对长期临床显著前列腺癌(csPCa)风险的 stratified 作用。中位随访5.5年,7年csPCa累积发生率整体为7.1%,PSAD<0.10、0.10-<0.15和≥0.15 ng/mL²组分别为5.5%、13.8%和11.9%(P<0.001)。PSAD可分层长期风险,支持风险适应随访。
要点
- MRI阴性后PSAD<0.10 ng/mL²组7年csPCa累积发生率最低(5.5%),但仍需定期PSA随访。
- PSAD≥0.10 ng/mL²组csPCa风险显著升高(13.8%和11.9%),应加强监测。
- PSAD指导策略(每2年PSA检测,PSAD≥0.10触发复查MRI)可减少60% MRI和46%活检。
核心结论
- PSAD可对MRI阴性后的长期csPCa风险进行分层,支持在前列腺癌筛查中采用风险适应随访策略。
研究设计与样本
- 基于人群的随机Göteborg-2筛查试验的预设亚组分析,纳入1685例2015年10月至2021年6月接受PSA检测且初次MRI阴性的男性,随访至2024年9月30日。
主要发现
- 中位随访5.5年,诊断160例前列腺癌,其中80例csPCa(Gleason≥3+4),包括22例Gleason≥4+3。
- 7年csPCa累积发生率整体7.1%,PSAD<0.10、0.10-<0.15和≥0.15 ng/mL²组分别为5.5%、13.8%和11.9%(PSAD<0.10 vs 较高两组P<0.001)。
- 87%的重复MRI保持阴性;PSAD<0.10组仍发生42例csPCa,包括12例Gleason≥4+3。
- PSAD指导策略(每2年PSA检测,PSAD≥0.10 ng/mL²触发复查MRI)可减少60% MRI使用和46%活检,使临床不显著前列腺癌检出减半,并使17%的csPCa诊断延迟(包括10例Gleason 3+4和1例Gleason≥4+3)。
临床怎么用
- 对MRI阴性男性,可采用PSAD分层:PSAD<0.10 ng/mL²者仍须定期PSA随访,PSAD≥0.10 ng/mL²者考虑更密切监测或复查MRI。
- PSAD指导的随访策略可减少不必要的MRI和活检,但需权衡部分csPCa诊断延迟的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether prostate-specific antigen density (PSAD) stratifies long-term risk of clinically significant prostate cancer (csPCa) after a negative magnetic resonance imaging (MRI; Prostate Imaging-Reporting and Data System score ≤2) and to evaluate the potential of PSAD to guide follow-up in a screening setting. PATIENTS AND METHODS: This pre-specified sub-analysis of the population-based, randomised Göteborg-2 screening trial included 1685 men who underwent PSA testing between October 2015 and June 2021 and had a subsequent negative initial MRI. Follow-up continued until 30 September 2024. The primary endpoint was cumulative incidence of csPCa (Gleason score ≥3 + 4). Men were categorised by baseline PSAD (<0.10, 0.10 to <0.15, and ≥0.15 ng/mL2). Cumulative incidence was estimated using Kaplan-Meier methods and compared using the log-rank test. The clinical implications of PSAD-based follow-up strategies were explored. RESULTS: Over a median follow-up of 5.5 years, 160 PCas were diagnosed, of which 80 were csPCa, including 22 cases of Gleason score ≥4 + 3. At 7 years, cumulative csPCa incidence was 7.1% overall and 5.5%, 13.8%, and 11.9% in the PSAD <0.10, 0.10 to <0.15, and ≥0.15 ng/mL2 groups, respectively (P < 0.001 for PSAD <0.10 ng/mL2 vs both higher groups). Overall, 87% of repeat MRIs remained negative. Although men with baseline PSAD <0.10 ng/mL2 had the lowest overall risk, 42 csPCas occurred in this group, including 12 Gleason score ≥4 + 3, emphasising the importance of continued regular PSA-based follow-up. A PSAD-guided strategy with biennial PSA testing and repeat MRI triggered by PSAD ≥0.10 ng/mL2 could reduce MRI use by 60% and biopsies by 46%, halve detection of clinically insignificant PCa, and delay csPCa diagnosis in 17% of cases including 10 men with Gleason score 3 + 4 and one with Gleason score ≥4 + 3. CONCLUSIONS: The PSAD stratifies long-term risk of csPCa after a negative MRI and supports risk-adapted follow-up in PCa screening.
引用
- Möller F, Månsson M, Hellström M, et al. The role of PSA density in the follow up of men with a negative MRI in the Göteborg-2 trial. BJU Int. 2026. PMID: 42759951. doi:10.1111/bju.70450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。